Tags : Evaluate

Pfizer Signs an Agreement with SpringWorks to Evaluate Nirogacestat +

Shots:   Pfizer to sponsor & conduct P-Ib/II study evaluating the safety, tolerability, and preliminary efficacy of dual regimen and will assume costs of study & other expenses related to IP rights.  The companies will form a joint development committee to manage clinical study which is anticipated to commence in H1’21 The focus of the collaboration […]Read More

Janssen Collaborates with SpringWorks to Evaluate Nirogacestat + Teclistamab for

Shots: The companies will evaluate SpringWorks’ Nirogacestat (GSI) in combination with Janssen’s Teclistamab (Ab targeting BCMA and CD3) in patients with r/r MM. The companies anticipate commencing the study by early 2021 Janssen to sponsor and conduct a P-I study assessing the safety, tolerability, and preliminary efficacy of the combination, and will assume all costs […]Read More

Chugai and Takeda Collaborate to Evaluate the Combination Therapy for

Shots: Following a joint clinical research agreement between Roche and Exelixis and in conjunction with certain rights granted in Japan, Chugai and Takeda will study Tecentriq (atezolizumab) and Cabometyx (cabozantinib) as a combination therapy in Japan The three global P- III CONTACT studies are ongoing to investigate the combination of atezolizumab and cabozantinib as a […]Read More

Roche Expands its Collaboration with Immunomedics to Evaluate Tecentriq Based

Shots: The companies extend their existing collaboration to evaluate Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) in combination with Tecentriq (atezolizumab) in patients with mUC and mNSCLC. The partners have ongoing collaboration in 1L metastatic triple-negative BC Roche will conduct two P-Ib/II studies utilizing MORPHEUS platform. The MORPHEUS-mUC study will evaluate Tecentriq + Trodelvy vs Tecentriq as monothx. […]Read More

Regeneron with its Partner NIAID Report the Initiation of P-III

Shots: The P-III trial involves assessing REGN-COV2 with an expected enrollment of 2000 patients at 100 sites which will be evaluated to prevent infection among uninfected people who have had close exposure to a COVID-19 patient REGN-COV2 is also being evaluated in P-II/III portion of two P-I/II/III trials testing the cocktail’s ability to treat hospitalized […]Read More

BMS Signs a Clinical Trial Collaboration with UbiVac to Evaluate

Shots: The two companies collaborated to evaluate the safety, tolerability, and preliminary efficacy of UbiVac’s DPV-00 in combination with BMS’ anti-OX40 (BMS-986178) combined with Opdivo (nivolumab) The P-Ib study will test the hypothesis that combination immunotherapy with the DPV-001 vaccine and anti-OX40 will boost anticancer immunity in patients with advanced TNBC UbiVac’s DRibble Platform Vaccine, […]Read More